Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $20.00 (from $28.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
